Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:2.6.1.2 (alanine aminotransferase)
26,722 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The polymerase chain reaction with prior reverse transcription of RNA into cDNA was applied to hepatitis C virus RNA detection in human serum samples of different origin. In order to eliminate false negative results, the following steps were optimized: RNA extraction, reverse transcription, and oligonucleotide primer selection. We compared different RNA extraction methods using guanidinium salt/detergent and proteinase K digestion/phenol extraction, and tested virus particle enrichment with polyethylene glycol precipitation and ultracentrifugation. RNA extraction with guanidinium salt/detergent was the most efficient method. Ultracentrifugation of single samples did not improve hepatitis C virus RNA detection. Polyethylene glycol precipitation performed poorly. Recombinant thermostable reverse transcriptase produced cDNA from fewer samples than did Moloney murine leukaemia virus reverse transcriptase. Nested oligonucleotide primers from the 5'-terminal non-coding region of the hepatitis C virus genome amplified cDNA from more samples than did primers from the coding regions. Thirty six anti-hepatitis C virus antibody positive samples were tested; nested primers (nucleotides 6 to 327 and 15 to 288) yielded 21 amplificates, whereas primers from the coding region produced 16 amplificates (nucleotides 4684-5276) and 5 amplificates (nucleotides 5166-5270), respectively. The most efficient combination of steps was RNA extraction with guanidinium salt solution, reverse transcription with Moloney murine leukaemia virus reverse transcriptase and nested polymerase chain reaction primed with primers from the 5'-terminal non-coding region of the hepatitis C virus genome. Other combinations produced more false negative results. Three different groups of anti-hepatitis C virus antibody positive individuals had markedly different viraemia patterns: Hepatitis C virus RNA was detected in the sera of only 10% of anti-hepatitis C virus antibody positive blood donors, but in 90% of anti-hepatitis C virus antibody positive patients with clinically manifest hepatitis C, and 90% of anti-hepatitis C virus antibody positive haemophiliacs who had received plasma products in the past which had not been virus-inactivated. No hepatitis C virus RNA could be detected in the sera of 450 anti-hepatitis C virus antibody negative blood donors with elevated serum alanine aminotransferase catalytic concentrations.
...
PMID:Improved detection of hepatitis C virus RNA by reverse transcription and polymerase chain reaction. 128 41

The effects of vitamin K3 treatment on the pharmacokinetics and metabolism of (+)-propranolol and the consequences of hepatic injury associated with vitamin K3 treatment were examined in groups of male Sprague-Dawley rats. When vitamin K3 (20 mg/kg) in polyethylene glycol 300 (PEG 300) was coinfused with (+)-propranolol (2 mg/kg) into the pyloric vein (a tributary flowing directly into the hepatic portal vein), a significant decrease in the intrinsic clearance of total drug (CLint) from 94.1 +/- 50.1 to 32.9 +/- 11.5 ml/min/kg was observed (p less than 0.01 vs. vehicle control). However, a lower dose of vitamin K3 (2 mg/kg in PEG 300) had little effect on this parameter. Interestingly, the PEG 300 vehicle control group exhibited a significantly (p less than 0.05) higher CLint than that observed in a saline control group (94.1 +/- 50.1 vs. 45.9 +/- 13.7 ml/min/kg). This difference appeared to be due to an increase in the free fraction of propranolol caused by PEG 300, because in vitro addition of this solvent to serum (at estimated in vivo concentrations) with or without added vitamin K3 doubled propranolol free fraction. Furthermore, rats that received the high dose vitamin K3 (20 mg/kg) treatment exhibited a pronounced increase in the serum concentration of enzymes of hepatic origin (alanine aminotransferase and sorbitol dehydrogenase) and in the incidence of hepatic necrosis. It was also observed that high-dose vitamin K3 treatment caused only minor changes in the urinary recovery of propranolol metabolites.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:The influence of vitamin K3 treatment on the pharmacokinetics and metabolism of (+)-propranolol in the rat. 135 23

At ambient conditions, the low vapor pressure of ethylene glycol monohexyl ether (EGHE) allows for a maximum vapor concentration of approximately 85 ppm. In an acute inhalation study on Wistar albino rats, a 4-hr exposure to 83 ppm EGHE produced no clinical signs, body weight effects, mortality, or macroscopic lesions in thoracic or abdominal organs. Fischer 344 rats exposed for 9 days (6 hr/day) over an 11-day period, to 0 (control), 19, 41, or 84 ppm EGHE had decreased body weight gains and increased liver to body weight values at 84 ppm EGHE. No alterations of the hematology parameters or the morphology of the testes or liver were observed. In a subsequent study, rats were exposed to mean EGHE concentrations of 0 (control), 20, 41, or 71 ppm for 6 hr/day, 5 days/week, for 13 weeks. Urogenital wetness was observed in all EGHE-exposed groups of females and in males of the 71-ppm group. Decreased body weight gains were observed in both sexes of the 71-ppm group, and a slight decrease was also observed in females of the 41-ppm group. Increased absolute and/or relative liver weights were observed in both sexes of the 71-ppm group and to a lesser extent in the 41-ppm group. Possibly related to these findings in the liver were decreases in serum transaminases (aspartate and alanine aminotransferase) and sorbitol dehydrogenase, with an increase in alkaline phosphatase observed in the 71-ppm group of female rats. However, there were no gross or histopathologic lesions found to indicate impairment of the liver.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Acute, 9-day, and 13-week vapor inhalation studies on ethylene glycol monohexyl ether. 355 32

Adult male rats (Crl:COBS CD (SD)BR) were given undiluted ethylene glycol monobutyl ether (EGBE) by gavage in doses of 222, 443, or 885 mg/kg/day, 5 days/week over a 6-week period. A dose-dependent decrease, which was statistically significant at the high dose, was seen in body weight gain. Feed consumption was also significantly reduced at the 885-mg/kg dose. The most significant toxic effects produced by EGBE were on the red blood cells including a significant dose-dependent decrease in hemoglobin concentration, red blood cell counts, and mean corpuscular hemoglobin concentration. Mean corpuscular hemoglobin and mean corpuscular volume were increased at all dose levels. Effects secondary to the red cell effects included increased spleen weights, splenic congestion, and hemosiderin accumulation in the liver and kidneys. Relative liver weights and serum alkaline phosphatase (443- and 885-mg/kg doses) and serum alanine aminotransferase (885-mg/kg dose) levels were increased. Glucose was significantly reduced in the animals given 885 mg/kg/day. EGBE had no adverse effects on the testes, bone marrow, thymus, or white blood cells.
...
PMID:Subchronic oral toxicity of ethylene glycol monobutyl ether in male rats. 369 24

Polyethylene glycol-6000 (PEG) was evaluated as a clearing agent for lipemic serum from dogs. Effects of PEG-treatment in lipemic and non-lipemic samples were determined for 13 chemical and enzymatic assays (glucose, BUN, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, amylase, total protein, albumin, sodium, potassium, chloride, phosphorus, and calcium). Control samples for lipemic sera were prepared by ultracentrifugation. Treatment with PEG cleared all lipemic samples. Regression lines for all lipemic samples were highly significant (P less than 0.0001) and the SD of the control values around the regression lines were small compared with the mean value for an assay. The technique was simple, quick, and inexpensive. With proper validation, reliable predictions of true serum values could be calculated for lipemic serum samples for all assays studied.
...
PMID:Polyethylene glycol-6000 as a clearing agent for lipemic serum samples from dogs and the effects on 13 serum assays. 649 14

Wistar male rats were exposed by inhalation to 50, 100 or 400 ppm of ethylene glycol monomethyl ether (EGME) for 1 to 2 weeks. The overall hepatic drug oxidation reactions, O-deethylation of 7-ethoxycoumarin and 7-ethoxyresorufin and cytochrome P-450 content were only slightly affected by the EGME exposures. NADPH cytochrome c reductase activity showed a tendency toward a dose-dependent decrease in liver, the activity being 73% and 64% of that in the controls after one and two weeks of exposure, at 400 ppm respectively. UDP glucuronosyl transferase activity exhibited a dose-dependent enhancement in liver microsomes after exposure for two weeks to EGME. The enhancement was 1.3- 1.7- and 3.0 fold with exposure to 50, 100 and 400 ppm of EGME respectively. After exposure for one week the UDPglucuronosyltransferase activity in kidney microsomes was similarly enhanced. A dose-related increase in measurable UDPglucuronosyltransferase activity was also obtained in Triton X-100 treated hepatic microsomes. GSH levels of the liver and kidneys in EGME treated animals showed a tendency towards a dose-dependent increase. The activities of low-Km and high-Km aldehyde dehydrogenases in liver were decreased 6 - 14% of that in the controls with exposure to 400 ppm of EGME when glycolaldehyde was used as a substrate. Serum alanine aminotransferase activity was not influenced by inhalation exposures to EGME.
...
PMID:Dose-dependent toxicity of ethylene glycol monomethyl ether vapour in the rat. 680 Jul 97

2-Methoxyethanol (ethylene glycol monomethyl ether) (EGME), is one of the most commonly used solvents for industrial and consumer products. Although the solvent has been shown to be a reproductive toxin the genotoxic activities of EGME especially its metabolites, have not been adequately investigated. The mutagenicity and cytotoxicity of EGME and its major metabolites, methoxyacetaldehyde (MALD) and methoxyacetic acid (MAA) in Chinese hamster ovary (CHO) cells were therefore examined by us. We have determined the mutagenicity of these compounds at the hypoxanthine-guanine phosphoribosyltransferase (hprt) locus in CHO-K1-BH4 cells (CHO/HPRT assay) and the xanthine-guanine phosphoribosyl transferase (gpt) locus in CHO AS52 cells (AS52/GPT assay). The results show that these chemicals are not mutagenic to the hprt locus in CHO-K1-BH4 cells either with or without rat liver S9 mix as the metabolic activating system. With AS52 cells, only MALD is mutagenic in the absence of S9. It induced a dose-dependent mutagenic response. A dose-dependent cytotoxicity was induced by all compounds in both cell lines. MALD is the most and EGME is the least cytotoxic compounds. Our study shows that a metabolite of EGME, MALD, is highly cytotoxic and likely induces deletion-type mutations in AS52 cells. The genotoxic effect of EGME is, therefore, dependent upon its metabolism and its detection is dependent upon the assays used.
...
PMID:Mutagenicity and cytotoxicity of 2-methoxyethanol and its metabolites in Chinese hamster cells (the CHO/HPRT and AS52/GPT assays). 767 57

The hepatotoxicity of 1,2-dichlorobenzene (1,2-DCB) was studied in Fischer-344 (F344) rats administered methyl palmitate (MP) to inhibit Kupffer cell function or superoxide dismutase (conjugated to polyethylene glycol, i.e., PEG-SOD) to scavenge superoxide anions. In rats not pretreated with phenobarbital (PB), administration of either MP or PEG-SOD dramatically reduced the severity of 1,2-DCB-induced liver injury. Both agents reduced the elevations in plasma ALT activities by 80%. PEG-SOD conferred protection when administered 2 hr before or 2 hr after 1,2-DCB. Light microscopic examination of H & E-stained liver sections confirmed that the reductions in plasma ALT activities reflected protection from hepatocellular injury. Interestingly, MP did not protect against 1,2-DCB-induced hepatotoxicity in PB-pretreated rats. The degree of inhibition of 1,2-DCB hepatotoxicity by PEG-SOD in PB-pretreated animals was also less than that in normal rats and was not significantly different. The lack of a significant inhibition of the PB-potentiated hepatotoxicity by both PEG-SOD and MP suggests that reactive oxygen species released from a nonparenchymal source were not as crucial to the 1,2-DCB hepatotoxicity in the PB-pretreated rats as in the normal rats. Our results using both MP and PEG-SOD support the hypothesis that reactive oxygen species released from Kupffer cells play a major role in the progression of 1,2-DCB hepatotoxicity in the F344 rat.
...
PMID:Modulation of 1,2-dichlorobenzene hepatotoxicity in the Fischer-344 rat by a scavenger of superoxide anions and an inhibitor of Kupffer cells. 838 65

Pretreatment of rats with large doses of vitamin A (VA) potentiates the hepatotoxicity of CCl4. Because our previous studies indicate that VA treatment does not enhance CCl4 metabolism but does enhance CCl4-induced lipid peroxidation and activates liver Kupffer cells to release increased amounts of oxygen-centered free radicals, the current studies were designed to determine if VA treatment potentiates CCl4-induced liver injury through increased release of reactive oxygen species. Plasma clearance of colloidal carbon, an index of Kupffer cell phagocytic activity, was enhanced two- to threefold in rats treated for 7 days with VA (retinol, 250,000 IU/kg per day). Accordingly, VA treatment alone caused Kupffer cell activation. To determine if these activated Kupffer cells could potentiate hepatic injury through release of reactive oxygen species upon CCl4 challenge, polyethylene glycol coupled-superoxide dismutase (PEG-SOD, 10,000 IU/kg) or -catalase (PEG-CAT, 40,000 IU/kg) was given iv 2 hr after CCl4 (0.15 ml/kg, ip) to control or VA-pretreated rats to quench any released reactive oxygen. PEG-SOD and PEG-CAT effectively blocked VA potentiation of CCl4 liver injury as assessed at 24 hr by change in plasma ALT. Methylpalmitate (MP, 2 g/kg), an inhibitor of Kupffer cell phagocytosis and related oxygen burst, also blocked the potentiation of liver injury when given iv 24 hr before CCl4 to VA-pretreated rats. At the doses used, PEG-SOD or PEG-CAT did not influence CCl4 toxicity in control rats (at 0.15 or 2 ml CCl4/kg). Importantly, SOD, CAT, and MP blocked the enhanced lipid peroxidation induced by CCl4 in VA-pretreated rats. From these findings we conclude that the potentiation of CCl4 liver injury by VA pretreatment is mediated, at least in part, by active oxygen species released from Kupffer cells and possibly other macrophages that are activated by VA. Supporting this conclusion is the failure of VA pretreatment to increase the release of LDH from suspension of hepatocytes incubated with CCl4.
...
PMID:Vitamin A potentiation of carbon tetrachloride hepatotoxicity: role of liver macrophages and active oxygen species. 848 Mar 39

The aim of this study was to determine whether antibodies to HCV can be hidden in immunocomplex aggregates in anti-hepatitis C virus (HCV) negative, HCV-RNA positive patients and whether their presence could be related to HCV viral load or HCV genotype. Sera (23 in toto) from patients with elevated alanine aminotransferase (ALT) levels and negative for anti-HCV but positive for HCV-RNA and the immunocomplex aggregates (precipitate with PEG 6000 and glycine 1 M) were studied. The sera were treated using a rapid, simple new ELISA which disrupted the immunocomplex aggregates. Sera from ten patients were tested anti-HCV positive after immunocomplex disruption. No correlation with age, sex, ALT level, viral load or HCV genotype was observed. In some patients anti-HCV antibodies were hidden in circulating antibody/antigen complexes which could be dissociated with a simple, inexpensive and rapid protocol; therefore it can provide a valuable addition to the diagnosis of HCV infection and it may prevent some cases of post-transfusion hepatitis.
...
PMID:Anti-hepatitic C virus antibodies hidden in circulating antibody/antigen aggregates in HCV-RNA positive patients. 1103 47


1 2 3 4 5 6 7 8 9 10 Next >>

---